

Kan He

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11193603/publications.pdf>

Version: 2024-02-01

35
papers

3,022
citations

201674

27
h-index

361022

35
g-index

35
all docs

35
docs citations

35
times ranked

2504
citing authors

#	ARTICLE	IF	CITATIONS
1	Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans. <i>Drug Metabolism and Disposition</i> , 2009, 37, 74-81.	3.3	561
2	Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1 <i>H</i> -pyrazolo[3,4- <i>c</i>]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 5339-5356.	6.4	387
3	Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice. <i>Chemical Research in Toxicology</i> , 1998, 11, 252-259.	3.3	307
4	In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies. <i>Drug Metabolism and Disposition</i> , 2010, 38, 448-458.	3.3	219
5	Metabolism and Disposition of Dasatinib after Oral Administration to Humans. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1357-1364.	3.3	170
6	METABOLIC ACTIVATION OF TROGLITAZONE: IDENTIFICATION OF A REACTIVE METABOLITE AND MECHANISMS INVOLVED. <i>Drug Metabolism and Disposition</i> , 2004, 32, 639-646.	3.3	115
7	Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban. <i>Drug Metabolism and Disposition</i> , 2013, 41, 827-835.	3.3	109
8	Comparative Metabolism of ¹⁴ C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1738-1748.	3.3	99
9	Structure-Based Design of Novel Guanidine/Benzamidine Mimics: A Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 4405-4418.	6.4	85
10	Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2011, 36, 129-139.	1.6	78
11	Bergamottin contribution to the grapefruit juice?felodipine interaction and disposition in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 607-617.	4.7	75
12	An algorithm for thorough background subtraction from high-resolution LC/MS data: application to the detection of troglitazone metabolites in rat plasma, bile, and urine. <i>Journal of Mass Spectrometry</i> , 2008, 43, 1191-1200.	1.6	70
13	1-[3-Aminobenzisoxazol-5-yl]-3-trifluoromethyl-6-[2-(3-(<i>R</i>)-hydroxy- <i>N</i> -pyrrolidinyl)methyl-[1,1-biphen-4-yl]-1,4,5,6-tetrahydro] (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4141-4147.	2.2	58
14	Tissue Distribution and Elimination of [¹⁴ C]Apixaban in Rats. <i>Drug Metabolism and Disposition</i> , 2011, 39, 256-264.	3.3	57
15	Sulfation of <i>O</i> -Demethyl Apixaban: Enzyme Identification and Species Comparison. <i>Drug Metabolism and Disposition</i> , 2009, 37, 802-808.	3.3	54
16	Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: Discovery of novel, highly potent inhibitors of Factor Xa. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4118-4123.	2.2	49
17	Lacteal Secretion, Fetal and Maternal Tissue Distribution of Dasatinib in Rats. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2564-2570.	3.3	49
18	Investigating the Enteroenteric Recirculation of Apixaban, a Factor Xa Inhibitor: Administration of Activated Charcoal to Bile Duct-Cannulated Rats and Dogs Receiving an Intravenous Dose and Use of Drug Transporter Knockout Rats. <i>Drug Metabolism and Disposition</i> , 2013, 41, 906-915.	3.3	49

#	ARTICLE	IF	CITATIONS
19	Reductive Isoxazole Ring Opening of the Anticoagulant Razaxaban Is the Major Metabolic Clearance Pathway in Rats and Dogs. <i>Drug Metabolism and Disposition</i> , 2008, 36, 303-315.	3.3	48
20	Identification of the Heme Adduct and an Active Site Peptide Modified during Mechanism-Based Inactivation of Rat Liver Cytochrome P450 2B1 by Secobarbital. <i>Chemical Research in Toxicology</i> , 1996, 9, 614-622.	3.3	44
21	Biotransformation of [¹⁴ C]Dasatinib: In Vitro Studies in Rat, Monkey, and Human and Disposition after Administration to Rats and Monkeys. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1341-1356.	3.3	40
22	Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2011, 26, 514-526.	5.2	37
23	Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2845-2849.	2.2	32
24	Preclinical Pharmacokinetic and Metabolism of Apixaban, a Potent and Selective Factor Xa Inhibitor. <i>Blood</i> , 2006, 108, 910-910.	1.4	32
25	Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 749-754.	2.2	31
26	THE CHIMPANZEE (PAN TROGLODYTES) AS A PHARMACOKINETIC MODEL FOR SELECTION OF DRUG CANDIDATES: MODEL CHARACTERIZATION AND APPLICATION. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1359-1369.	3.3	29
27	Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5584-5589.	2.2	28
28	Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 1432-1437.	2.2	19
29	Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6481-6488.	2.2	19
30	Highly efficacious factor Xa inhibitors containing β -substituted phenylcycloalkyl P4 moieties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 462-468.	2.2	16
31	Synthesis and biological evaluation of 6,7-dihydroxybergamottin (6,7-DHB), a naturally occurring inhibitor of cytochrome P450 3A4. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1997, 7, 2593-2598.	2.2	15
32	Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 5041-5048.	2.2	15
33	Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 70-80.	2.1	15
34	Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3341-3345.	2.2	9
35	Troglitazone Thiol Adduct Formation in Human Liver Microsomes: Enzyme Kinetics and Reaction Phenotyping. <i>Drug Metabolism Letters</i> , 2008, 2, 184-189.	0.8	2